CONRAY 325 Drug Patent Profile
✉ Email this page to a colleague
When do Conray 325 patents expire, and when can generic versions of Conray 325 launch?
Conray 325 is a drug marketed by Mallinckrodt and is included in one NDA.
The generic ingredient in CONRAY 325 is iothalamate sodium. There is one drug master file entry for this compound. Additional details are available on the iothalamate sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CONRAY 325?
- What are the global sales for CONRAY 325?
- What is Average Wholesale Price for CONRAY 325?
Summary for CONRAY 325
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 20 |
| Patent Applications: | 683 |
| DailyMed Link: | CONRAY 325 at DailyMed |
US Patents and Regulatory Information for CONRAY 325
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt | CONRAY 325 | iothalamate sodium | INJECTABLE;INJECTION | 017685-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
